- Home
- AMS vs ALLR Comparison
AMS vs ALLR Comparison
Compare AMS & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- ALLR
- Stock Information
- Founded
- AMS 1980
- ALLR 2004
- Country
- AMS United States
- ALLR United States
- Employees
- AMS N/A
- ALLR N/A
- Industry
- AMS Medical Specialities
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- ALLR Health Care
- Exchange
- AMS Nasdaq
- ALLR Nasdaq
- Market Cap
- AMS 17.2M
- ALLR 15.8M
- IPO Year
- AMS N/A
- ALLR N/A
- Fundamental
- Price
- AMS $2.44
- ALLR $1.70
- Analyst Decision
- AMS
- ALLR Strong Buy
- Analyst Count
- AMS 0
- ALLR 1
- Target Price
- AMS N/A
- ALLR $9.25
- AVG Volume (30 Days)
- AMS 101.9K
- ALLR 620.1K
- Earning Date
- AMS 11-12-2025
- ALLR 11-13-2025
- Dividend Yield
- AMS N/A
- ALLR N/A
- EPS Growth
- AMS N/A
- ALLR N/A
- EPS
- AMS N/A
- ALLR N/A
- Revenue
- AMS $29,251,000.00
- ALLR N/A
- Revenue This Year
- AMS $5.06
- ALLR N/A
- Revenue Next Year
- AMS N/A
- ALLR N/A
- P/E Ratio
- AMS N/A
- ALLR N/A
- Revenue Growth
- AMS 26.61
- ALLR N/A
- 52 Week Low
- AMS $2.27
- ALLR $0.61
- 52 Week High
- AMS $3.59
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- AMS 48.23
- ALLR 58.30
- Support Level
- AMS $2.45
- ALLR $1.54
- Resistance Level
- AMS $2.58
- ALLR $1.77
- Average True Range (ATR)
- AMS 0.14
- ALLR 0.12
- MACD
- AMS 0.01
- ALLR -0.01
- Stochastic Oscillator
- AMS 15.28
- ALLR 66.67
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.